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Abstract: Inherited retinal dystrophies, such as retinitis pigmentosa (RP), include a group of relatively rare hereditary 
diseases caused by mutations in genes that code for proteins involved in the maintenance and function of the 
photoreceptor cells (cones and rods). The different forms of RP consist of progressive neurodegenerative disorders which 
are generally related to various and severe limitations of visual performances. In the course of typical RP (rod-cone 
dystrophy), the affected individuals first experience night-blindness and/or visual field constriction (secondary to rod 
dysfunctions), followed by variable alterations of the central vision (due to cone damages). On the other hand, during the 
atypical form of RP (cone-rod dystrophy), the cone’s functionalities are prevalently disrupted in comparison with the 
rod’s ones. The basic diagnosis of RP relies upon the documentation of unremitting loss in photoreceptor activity by 
electroretinogram and/or visual field testing. The prevalence of all RP typologies is variably reported in about one case for 
each 3000-5000 individuals, with a total of about two millions of affected persons worldwide. The inherited retinal 
dystrophies are sometimes the epiphenomenon of a complex framework (syndromic RP), but more often they represent an 
isolated disorder (about 85-90 % of cases). Although 200 causative RP mutations have been hitherto detected in more than 
100 different genes, the molecular defect is identifiable in just about the 50% of the analyzed patients with RP. Not only 
the RP genotypes are very heterogeneous, but also the patients with the same mutation can be affected by different 
phenotypic manifestations. RP can be inherited as autosomal dominant, autosomal recessive or X-linked trait, and many 
sporadic forms are diagnosed in patients with no affected relatives. Dissecting the clinico-genetic complexity of RP has 
become an attainable objective by means of large-scale research projects, in which the collaboration between 
ophthalmologists, geneticists, and epidemiologists becomes a crucial aspect. In the present review, the main issues 
regarding clinical phenotyping and epidemiologic criticisms of RP are focused, especially highlighting the importance of 
both standardization of the diagnostic protocols and appropriateness of the disease’s registration systems. 
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INTRODUCTION 
  The most frequent hereditary disorders of the posterior 
segment of the eye are identifiable in the all-encompassing 
taxonomic terminology of “inherited retinal dystrophies” 
which are also habitually, even if, imprecisely named 
retinitis pigmentosa (RP) [1-6]. Despite the relatively high-
rate of occurrence of this heterogeneous pathologic category, 
whose prevalence is variable reported in 1 case for each 
3000-5000 individuals [7-23] but can arrives to about 1:2400 
or more within close ethnic group knitted by blood 
relationship or the same kinship [24, 25], the various RP   
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forms are labeled as rare diseases. Rare diseases, including 
those of genetic origin such as RPs, are life-threatening or 
chronically debilitating diseases which are of such low 
prevalence that special combined efforts are needed to 
address them. However, there is no single, unequivocal, and 
universally-accepted definition of rare diseases. Some 
designations are based exclusively on the number of people 
living with a disease, and other categorizations involve 
different factors, such as the existence of adequate treatments 
or the disease’s severity. Similarly, the definitions used in 
the medical literature or by the Health Systems are again 
extremely various and, ranging from 1:1000 to 1:200000 in 
consideration of the disease’s prevalence among general 
population [26]. 
  The numerous typologies of RP represent the most 
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from time to time, the scientific literature on RPs has 
reported the clinical heterogeneity, the phenotypic inter- or 
intrafamilial variability, and the large genotypic multiplicity 
which becomes especially evident examining different ethnic 
clusters [6-25, 27-42]. By means of an extreme cataloging 
approach manner, to obtain the maximal simplification of an 
extraordinarily intricate classification, but also knowing that 
in this way many chances to consider genotype-phenotype 
associations are lost, the different forms of RP can be 
divided into two main groups: i. rod-cone dystrophy (RCD) 
in which the rods are prevalently damaged (a RCD is 
diagnosed in about 80-90% of the total patients with RP and, 
thus, it can also be defined as typical RP); and ii. cone-rod 
dystrophy (CRD) in which the cones are mainly damaged (a 
CRD is diagnosed in about 10-20% of the total patients with 
RP and, thus, it can also be defined as atypical RP) [43, 44]. 
Several methods have been hitherto used to classify RPs: 
•  electroretinogram (ERG) to discriminate whether the 
alterations of the scotopic system (rods) predominate 
over those of the photopic one (cones) or vice versa; 
•  ophthalmoscopic retinal appearance (fundus oculi) to 
basically distinguish the localization and/or the 
characteristics of those peculiar degenerative changes 
observable in retina and retinal pigment epithelium 
(RPE), i.e. mid-peripheral or peripheral pigmentary 
deposits, sine pigment retinal aspect, retinitis punctata 
albescens with whitish spots, paravascular, sectorial, 
central or pericentral pigment deposits, and unilateral 
pigmentary lesions; 
•  mode of inheritance that includes monogenic 
autosomal dominant (AD), monogenic autosomal 
recessive (AR), monogenic dominant X-linked (XL) 
or, very rarely, monogenic recessive XL, digenic, and 
mitochondrial; 
•  age of onset that considers four possibilities for the 
beginning of specific RP symptoms and/or signs, 
detectable in children, adolescents, young adults or 
adults; 
•  molecular genetics that involves all the possible 
mutations causing the different RP phenotypes [6, 
42]. 
  These tapetum-retinal dystrophies are sometimes the 
epiphenomenon of a complex framework (syndromic RP in 
about 10-15% of cases), but more often they represent an 
isolated disorder (about 85-90 % of cases). In almost all 
cases, patients with syndromic RP are affected by a RCD, 
which usually resembles typical RP form. The more 
common RP-associated diseases are the following: 
•  Usher syndrome (type I, type II, type III, overall 
representing about 12% of RP), mainly related to 
neuro-sensorial hearing loss (secondary to disorders 
of cochlear cells) – the level of visual loss and, above 
all, hearing and balance loss depends on the Usher 
syndrome type; 
•  Bardet-Biedl syndrome, characterized by obesity, 
polydactyly, hypogonadism (especially in men), renal 
disorders and mental retardation; 
 
•  Laurence-Moon disease, characterized by mental 
retardation, hypogonadism, language impairment, 
ataxia, spastic paraplegia (without polydactyly, 
obesity, renal disorders); 
•  abetalipoproteinemia (Bassen-Kornzwig), characteri-
zed by lipoproteic dysmetabolism, malabsorption, 
progressive ataxic neuropathy, acanthocytosis; 
•  Alstrom disease, characterized by neurosensorial 
hearing loss, obesity, diabetes, dilated cardiomyo-
pathy, chronic renal and epatic disorders; 
•  Cockayane syndrome, characterized by neurological 
disfunctions and some problems in growing; 
•  Refsum disease, characterized by lipoproteic 
dysmetabolism, peripheral neuropathy, ataxia, 
anosmia, ichthyosis and epiphyseal dysplasia; 
•  Friedreck ataxia, characterized by secondary ataxia to 
progressive central nervous system damages, growing 
and language disorders, cardiomyopathy; 
•  Kearns Sayre syndrome, characterized by external 
progressive ophthalmoplegia, heart disorders, 
cerebellar ataxia (occasionally with dystonia, 
myopathy, neurosensorial hearing loss, dementia, 
cataract, proximal tubular renal acidosis, diabetes, 
growth retardation, hypoparathyroidism); 
•  Mucopolysaccharidosis, characterized by bone 
abnormalities, mental retardation, corneal defects. 
  Usher syndrome, in which RP is associated with neuro-
sensory deafness, represents the most frequent syndromic 
tapetum-retinal dystrophy [4, 8, 13, 15, 16].. 
  The phenotyping of both isolated and syndromic forms of 
RP can represent a very challenging task, that should be 
preferentially carried out in specialized referral Centers 
utilizing standardized diagnostic procedures and follow-ups. 
This clinical start-point is the necessary prerequisite to 
obtain an effectual collaboration among ophthalmologists, 
geneticists and epidemiologists, ideally articulated for a 
large-scale biobanking of patients inside each socio-sanitary 
catchment’s area. In fact, each patient with RP should be 
considered as a unique case on its own, in which the 
pathologic expressivity may be partially independent by the 
type of disease-gene but, at the same time and when it is 
possible, this patient should be also properly framed in well-
defined genealogic and epidemiologic contexts. In other 
words, during the routine clinical practice of each referral RP 
Center, a standardized patient’s phenotyping and monitoring 
should be realized to maximize, in the mid- or long-term: the 
appropriateness of both epidemiological and bio-bank 
registers (involving the proband and, if applicable or 
possible, also his/her family tree), the chance of success of 
the multifaceted DNA analyses and, consequently, the 
cost/benefit ratio of these biomolecular investigations. The 
aforementioned collaborative study-attitude appears to be 
necessary to worldwide face the new challenges concerning 
both the molecular diagnoses and the gene therapies in RP 
patients. Considering the extraordinary variability of the 
disease-genes responsible for RP, as well as of their 
modifiers [6, 27-42], the applicability of these approaches 
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nationally or internationally coordinated, clinico-genetic 
studies targeted within each ethnic group. 
CLINICAL PHENOTYPING AND DIAGNOSTIC 
PROTOCOLS 
  The patients referred to a RP Center usually come to our 
observation for the following functional symptoms, 
ophthalmoscopic signs and/or visual field (VF) patterns: 
•  night-blindness (nyctalopia), variable photophobia, 
initial slight deterioration of quantity and/or quality of 
visual acuity (VA) – which are often distinctive 
symptoms of RCD; 
•  decrease in VA (often with reduction of fluent-
reading), noteworthy photophobia, frequent 
dyschromatopsia, initial slight alteration of night-
vision – which are often distinctive symptoms of 
CRD; 
•  rearrangement of the retinal pigment epithelium 
(RPE), variable attenuation of the retinal vessels, 
pigmentary deposits resembling bone spicules and/or 
various degrees of retinal atrophy (typically evident 
in the mid-peripheral sectors of the retina) possibly 
associated with pallor or waxy-pallor of the optic disc 
and normal looking macula or fine macular lesions – 
which are often distinctive signs of RCD; 
•  rearrangement of the RPE, pigmentary deposits 
resembling bone spicules and/or various degrees of 
retinal atrophy (typically evident in macular area 
and/or posterior pole of the retina) eventually 
anticipated by fine macular lesions and pallor of the 
optic disc, and then possibly associated with different 
levels of attenuation of the retinal vessels and macular 
degeneration – which are often distinctive signs of 
CRD; 
•  VF patterns characterized by patchy losses of 
peripheral vision evolving to ring shape scotoma with 
variable risk of tunnel vision – which are often 
distinctive of RCD; 
•  VF patterns characterized by central scotoma, then 
associated with variable patchy losses of peripheral 
vision – which are often distinctive of CRD. 
  Considering these specific, even if variably severe, eye 
disorders, the diagnostic protocols for patients with 
ascertained or suspected RP can be schematized in: 
(A)  basic protocol including those assessments strictly 
necessary for the diagnosis of RP 
-  ophthalmologic examination (visual acuity, 
intraocular pressure, biomicroscopy of the ocular 
anterior segment and ophthalmoscopy of the ocular 
posterior segment) 
-  visual field test (manual and/or computerized) 
- electroretinogram (full-field, scotopic, photopic, 
flicker and/or pattern) 
- genetic  counseling 
 
(B)  full protocol including all those examinations useful 
for difficult differential diagnoses and/or complete 
patient’s phenotyping 
-  ophthalmologic examination (visual acuity, 
intraocular pressure, biomicroscopy of the ocular 
anterior segment and ophthalmoscopy of the ocular 
posterior segment) 
- contrast  sensitivity 
- color  vision 
-  visual field test (manual and/or computerized) 
- microperimetry 
- electroretinogram (full-field, scotopic, photopic, 
flicker and/or pattern) 
- micro-electroretinogram 
- multifocal  electroretinogram 
-  optical coherence tomography of the macular area 
-  optical coherence tomography of the peri-papillary 
retinal nerve fiber layer 
- auto-fluorescent  retinography 
-  multifocal visual evoked potential 
- retino-choroidal  angiography 
- genetic  counseling 
-  other particular, non-ophthalmologic, assessments 
necessary for the diagnosis of syndromic RP, such as 
audiometric and vestibular tests, olfactometric 
examination, renal echography, etc. 
  The evident complexity of this second protocol is further 
enhanced by the fact that for a consolidated diagnosis, also 
inclusive of an age-dependent RP staging of the disease’s 
expressivity, several patients should be monitored with 
periodical ophthalmologic checks for at least 24-36 months. 
The aspect of patient’s follow-up can become essential 
especially in the cases of RP diagnosed at an early stage of 
the disease; in fact, the prompt RP identification might 
represent the real turning-point on which are based current 
and, above all, future therapeutic possibilities for RP [45, 
46]. Therefore, considering that RP can be transmitted with 
all the typologies of mendelian inheritance, each patient with 
RP should be managed like a potential proband by both 
ophthalmologist and geneticist, aiming to define the risk of 
disease or of non-affected-carrier status in the other members 
of the patient’s family. 
BASIC NOTIONS FOR GENETIC COUNSELING 
  The RP can be present in different individuals and/or in 
different generations of the same family. The inheritance can 
be direct and characterized by vertical transmission in the 
genealogic tree (autosomal dominant RP, AD-RP), or 
indirect and characterized by horizontal transmission in the 
genealogic tree (autosomal recessive RP, AR-RP). In several 
families, the disease can be inherited through the X 
chromosome (X-linked RP, XL-RP), where only males are 
affected if they receive the disease-gene from the mother, 
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is present in a family and the available informations do not 
reveal any other case of RP in the genealogic tree, the 
disease should be labeled as sporadic RP. However, although 
in some cases these forms really begin in a normal family 
because the causal gene mutation occurs during the fetal 
development, in other cases they are wrongly defined as 
sporadic due to the loss or absence of disease’s informations 
in the past generations. Accurate ophthalmologic data of the 
proband and his/her relatives, together with a wide-ranging 
familial history, should be collected to efficiently guide the 
genetic counseling. This is a process by which patients 
and/or other family members, at risk of an inherited disorder 
such as RP, are advised about the typology and the possible 
consequences of the disorder, the probabilities of developing 
and/or transmitting it, and the options to prevent or treat it. 
This complex practice can be separated into two main 
aspects: diagnostic (the actual estimation of the risk) and 
supportive (the realistic explanation of the solutions). 
  The AD-RP typically has the following characteristics in 
the affected families: i. equal frequency in males and 
females; ii. vertical transmission of the disease-gene in the 
geologic tree; iii. procreative risk estimable around the 50%. 
According to this inheritance model, each patient with AD-
RP should have one affected parent, as well other affected 
ancestors, such as one grandfather and/or one or more 
granduncles. However, this is just a theoretical model 
because, sometimes, misdiagnosed forms of RP do not allow 
to compose a reliable genealogic tree. Considering all forms 
of RP, the occurrence of AD disorder varies among the 
different ethnic groups, with an estimated average frequency 
approximately of 30-40% of cases [6, 42, 45]. In families 
with AR-RP, the disease usually appears with the following 
features: i. equal frequency in males and females; ii. 
horizontal presence of affected individuals in the geologic 
tree; iii. two non-affected carriers have a procreative risk 
estimable around the 25%. It is necessary that two healthy 
individuals, both carriers of one copy of the mutated gene, 
procreate to having an affected child. This situation occurs 
more frequently in small communities where the probability 
of parental consanguinity is higher. The usual lack of vertical 
transmission can often result in a difficult family tree 
drawing. Likewise the AD form, the occurrence of AR-RP 
changes among the different ethnic groups, with an 
estimated average frequency approximately of 50-60% of 
cases [6, 42, 45]. The XL-RP forms are characterized by: i. 
mutant gene is on the X chromosome and, thus, all men who 
inherit the causative mutation are diseased; ii. affected males 
transmit their defective X chromosome to all daughters, who 
are labeled as obligate non-affected carriers; iii. female 
carriers pass the defective X chromosome to half of their 
sons (who will be affected by RP) and to half of their 
daughters (who will be RP carriers too). Although each 
patient with XL-RP should have the mother as obligate non-
affected carriers, in some families the misdiagnosing of this 
status does not allow to reliably compile the genealogic tree. 
The frequency of XL-RP is estimated around 5-15% of cases 
[6, 42, 45]. 
  Although the most RP cases are monogenic, digenic and 
mitochondrial forms of RP have been described. In the 
complex context concerning the molecular genetics of 
patients with RP, the possibility to identify phenotype-
genotype associations can be often frustrated by the 
existence of large genotypic diversity, unfeasibility in 
defining the inheritance model, racial variability of the 
causal gene mutations, inter- or intra-familial changeability 
of the phenotypic expressivity, and difficult clinical 
phenotyping of peculiar and/or advanced forms of RP [6-25, 
27-42]. Despite the increasing possibilities of molecular 
diagnosis, at present approximately 30-50% of diagnosed 
RPs are attributable to genes that remain yet unidentified. 
Moreover, many genes for RP are causative of a small 
percentage of cases, with the exception of the rhodopsin 
gene (present in about 20-25% of AD-RP), USH2A gene 
(present in about 15-20% of AR-RP especially including 
many Usher syndrome type II), and RPGR gene (present in 
about 65-70% of XL-RP) [6, 42, 45]. RP genes code for 
molecules involved in different physiopathologic 
mechanisms, such as: phototransduction cascade, vitamin A 
metabolism, structural or cyto-skeletal functions, interactive 
cell-cell signaling or synaptic interaction, intron-splicing of 
RNA, intracellular trafficking, maintenance of cilia/ciliated 
cells, pH regulation, phagocytosis and so on; even so, the 
inventory of the mutations, ascertained or suspected, is 
constantly getting longer coming over 200 mutations present 
in more than 100 different genes [6, 42, 45]. 
EPIDEMIOLOGY AND GENETICS 
  In the early 1980s, the overall rate of the numerous RP 
forms has been estimated in about 1 case per 3000-5000 
inhabitants of the United States [7, 8]. Starting from 1984, in 
some districts of United States, United Kingdom, France, 
Spain and Germany, as well as in Norway, Denmark and 
Slovenia, several epidemiologic investigations on RP have 
been conducted in homogeneous populations of Caucasian 
ethnicity [9-13, 15-18, 21, 22, 25]. In particular, a study 
carried out in the Northern France revealed a prevalence of 
inherited retinal dystrophies equal to 1:2409 within a 
population of about 4 million people [25]. Exclusively 
considering the diagnoses of RP, in 2002 the estimated 
disease’s prevalence was 1:3943 among Danish population 
[17] whereas in Norway, fifteen years before, it had been 
rated 1:4440 [13]. More recently, a study carried out in the 
Southern Germany has documented that approximately 8% 
of the cases of blindness was caused by tapeto-retinal 
degeneration [22]. 
  In other Countries, the available epidemiological data as 
regards of RP are still fragmentary and/or just partially 
accessible. In Veneto, a Region of the Northern Italy 
inhabited by about 4.9 million people, we have estimated 
that from 2006 to 2009 the official certifications of RP in the 
Rare Diseases Register are more than doubled. However, 
also the more recent estimation of RP prevalence, equal to 
about 1:8300, is still too much low in comparison with the 
data of the aforementioned European Countries [13, 17, 25]. 
On the other hand, exclusively considering the area where 
our specialized referral Center is activated from almost eight 
years (i.e. the Province of Padova inhabited by more than 
nine hundred thousand people), the certified RP diagnoses 
arrive to about 1 case per 5200 individuals. The considerable 
reduction of this epidemiologic and diagnostic gap indirectly 
emphasizes the importance of these peculiar clinico-
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patients, to manage both probands and their relatives, to 
support the geneticists during their awkward biomolecular 
investigations. In addition, the effectual collaboration 
between referral RP Centers and Associations of RP patients 
should promote a proper socio-sanitary awareness about this 
disease, especially in those districts characterized by an 
increased RP occurrence due to high rate of consanguinity. 
  In view of the above-reported findings of RP prevalence 
in Caucasian populations [13, 17, 25], more than 3000 Italian 
families counting about 12000-15000 patients with inherited 
retinopathies should be hypothetically registered and 
classified. Although a part of these families (patients) have 
been hitherto analyzed for the several known mutations 
associated with RP, the causative genetic alteration has been 
discovered just in fewer than 45-50% of patients, with the 
exception of XL-RP forms for which this percentage can 
arrive to 65-75%. These limited results in molecular 
diagnosis resemble those obtained in other Western 
Countries suggesting, once again, that it is necessary a more 
systematic, diffused and comprehensive clinico-genetic 
management of patients with inherited retinal dystrophies, in 
a context of a RP-dedicated health network. Considering 
that, at present, these groups of diseases are just very 
partially curable, molecular diagnosis represents one of the 
most relevant information for the patients suffering from RP, 
as well as for their families. In Mendelian diseases, such as 
the various forms of RP, the gene identification is 
traditionally based on two approaches: i. positional cloning 
of regions specifically linked to the disease by both linkage 
analysis and homozygosis mapping; ii. functional cloning of 
the genes involved in the pathogenetic mechanisms of the 
disease. However, during the last years, the use of high-
resolution genome-wide arrays has led to the characterization 
of several causative RP-associated genetic loci. Expectantly, 
the next widespread availability of new-generation 
sequencing machines (adapted for the clinical employment) 
will allow to simultaneously analyze all the genes associated 
with RP or, if certainly established the inheritance model 
(AD, AR or XL), all the genes associated with that specific 
hereditary pattern of RP. With the exploitation of these lab 
technologies, the molecular diagnostic tests of a RP patient 
and of his/her relatives may be carried out in one or just few 
months rather than one year or more, effectively supporting 
the advancement of an essential final necessity, i.e. the 
molecular classification of the RPs [6, 42]. In health and 
scientific fields, all the research programs aimed to more 
closely connect large database of RP cases or pedigrees with 
genetic studies on these groups of disorders are warranted to: 
i. take real clinical advantage of the high quantitative 
efficiency of the latest diagnostic methods regarding the 
already known RP mutations; ii. characterize novel disease-
genes associated with the numerous molecular forms of RP. 
In this way, it will be finally possible to give concrete 
diagnostic answers to a considerable part of RP patients 
starting from a large-scale attitude of good epidemiologic 
practice to arrive at a factual good clinical practice, mainly 
composed of proper phenotyping and biobanking. As 
recently indicated by the proponents of the European 
Glaucoma Society GlaucoGENE project, “The use of non-
specific or poorly defined phenotypes may partly explain the 
limited progress so far in glaucoma complex genetics” [47]. 
Referring to the RPs, this statement sounds more relevant 
than ever. In fact, only a synchronous advancement of the 
epidemiologic, clinical and genetic knowledges on RP will 
consent to effectually bridge the current gap from the lab to 
the patients. 
CONCLUSIONS 
  In several Health Systems, the overall management of the 
RP is difficult also because some important epidemiological 
issues are still unresolved for the lack of a shared and 
organized RP network, which is unavoidably related to risk 
of: i. quantitative underestimation of the disease; ii. limited 
socio-sanitary utility of the informative data included in the 
disease’s register. In view of the complexities inherent to an 
all-embracing approach toward RPs, the lack of an adequate 
epidemiologic register can have very negative impact on the 
diagnostic, preventive, therapeutic, rehabilitative and 
psychological management of many patients suffering from 
these dramatic eye diseases. In particular, an appropriate 
framework of a modern RP-database does not leave aside 
some critical aspects – of course, respecting both the privacy 
of each registered person and the willingness to share the 
data by the Health structures belonging to the certification-
system: 
•  standardization of the diagnostic protocols utilized for 
the ophthalmologic classification of the disease, also 
detailing, if any, the deficiencies and/or the weak-
points of this phenotyping procedure; 
•  large share of the methodology employed for the 
taxonomy of the inherited tapeto-retinal dystrophies; 
•  standardization of the approach utilized to stage the 
disease’s expressivity by means of an age-dependent 
grading system; 
•  report on both the therapeutic plans and the 
rehabilitative approaches dedicated to each affected 
individual; 
•  accurate clinical informations about other possible 
eye disorders associated with the tapeto-retinal 
degeneration, such as keratoconus, glaucoma, 
cataract, cystoid macular edema, Coats-like exudative 
vasculopathy, retinal angiomatous proliferation, 
choroidal neovascularization and so on; 
•  non-ophthalmologic clinical informations about the 
syndromic forms of the disease; 
•  description of the genealogic tree providing, if any, 
for the connections among that specific registered 
patient, the other affected relatives with a certified 
diagnosis and/or the non-affected (healthy) carriers of 
the family; 
•  informative electronic and anonymous links with the 
registry offices to possibly trace the first ancestral 
proband of the disease-gene and his/her area of birth; 
•  informations about the biobanking of blood, DNA or 
other biologic materials of the patient (if happened); 
•  report on the causative gene mutation (if definitely 
recognized); 
•  report about the presence of intra-familial 
homogeneity or heterogeneity in disease’s 
expressivity; Good Epidemiologic Practice in Retinitis Pigmentosa  Current Genomics, 2011, Vol. 12, No. 4    265 
•  report on the potential modifiers of the disease’s 
expressivity (inherited or acquired); 
•  obligation of patient’s certification or patient’s 
forwarding to a certifying Center by the 
ophthalmologist who identifies an affected individual; 
•  no intersection between the epidemiologic 
registration and legal-medicine implications, ensuring 
both the anonymity for the patient and the 
professional secrecy for the certifying physician. 
  In the next future, the deficiency in each of the above-
listed points can represent a negative aspect, potentially able 
to counteract the good clinical governance of severe rare 
diseases like RPs. Although the individuals with these 
neurodegenerative disorders represent a relatively small 
percentage in proportion to the general population, their 
socio-sanitary burden is undoubtedly of critical importance, 
especially considering the frequent early onset of the disease, 
the procreative risk of disease’s transmission and the almost 
total lack of effective therapeutic strategies. 
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